This article is for informational and educational purposes only and does not constitute medical advice. TA-1 is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Thymosin alpha-1 (Tα1; TA-1) is a 28-amino-acid peptide originally isolated from bovine thymic tissue by Goldstein and colleagues in the 1970s. It carries an N-terminal acetyl modification (Ac-Ser1) and a free acid C-terminus, with a molecular weight of approximately 3,108 Da. Thymosin alpha-1 is the founding member of the thymosin alpha family and corresponds to the N-terminal fragment of the full-length precursor protein prothymosin alpha, encoded by the PTMA gene. Research interest centers on its capacity to modulate innate and adaptive immune function: proposed mechanisms include activation of Toll-like receptor 2 (TLR2) and TLR9 signaling, promotion of dendritic cell maturation and Th1 polarization, and enhancement of natural killer (NK) cell activity. Unusually among compounds in this research catalog, thymosin alpha-1 has been evaluated in controlled human clinical trials, with published data in chronic hepatitis B, hepatitis C, and severe sepsis. The compound is sold commercially as Zadaxin (SciClone Pharmaceuticals) and is approved in some jurisdictions for hepatitis B and hepatitis C indications; it is not FDA-approved in the United States for any indication.
1. Background
1.1 Discovery and Thymic Origin
The thymus gland produces a spectrum of soluble factors collectively termed thymosins, which were first characterized by Abraham White and Allan Goldstein at the Albert Einstein College of Medicine in the mid-1960s. Initial efforts isolated a heterogeneous protein fraction designated thymosin fraction 5 (TF-5), which possessed lymphocyte-stimulating and immunorestorative properties in thymic-deficient animal models. Systematic purification of TF-5 over subsequent years yielded a series of distinct polypeptides designated the thymosin alpha, beta, and gamma families based on isoelectric point. Thymosin alpha-1 was isolated, fully sequenced, and chemically characterized by Low and Goldstein in 1979 [1], establishing its 28-amino-acid structure with N-terminal acetylation. The compound was subsequently confirmed as the N-terminal 28-residue fragment of prothymosin alpha, a highly acidic nuclear protein with roles in chromatin remodeling and gene expression regulation beyond its role as TA-1 precursor.
TA-1 is distinct from TB-500 (Thymosin Beta-4 fragment), which belongs to a structurally and functionally different thymosin family. Thymosin alpha-1 and thymosin beta-4 are unrelated peptides that share only the thymus-derived nomenclature; their sequences, molecular targets, and proposed mechanisms are entirely distinct.
1.2 Zadaxin and Clinical Development
Synthetic thymosin alpha-1 was developed as a pharmaceutical product under the brand name Zadaxin by Alpha-1 Biomedical (later acquired by SciClone Pharmaceuticals). Phase I–III trials were conducted primarily in Asia, Italy, and Eastern Europe through the 1990s and 2000s, targeting chronic hepatitis B, chronic hepatitis C, and as an adjunct immunomodulator in cancer patients receiving chemotherapy. Zadaxin received regulatory approval in the People’s Republic of China, Italy (briefly), and several Southeast Asian and Latin American countries. An FDA submission was filed but did not achieve approval; TA-1 is not approved for any indication in the United States or the European Union. Its use in clinical research studies, as well as the volume of controlled trial data published, is substantially greater than for most research peptides in this catalog.
1.3 Thymalin versus Thymosin Alpha-1
The term thymalin refers to a heterogeneous polypeptide extract prepared from bovine thymic tissue and is a distinct formulation from synthetic, sequence-defined thymosin alpha-1. Thymalin contains multiple thymic peptides and is not compositionally identical to purified recombinant or synthetic TA-1. The Khavinson group has studied thymalin and related thymic preparations in Russian clinical and longevity research contexts. These compounds share general immunomodulatory properties with TA-1 but should not be treated as equivalent for research purposes due to compositional differences.
2. Molecular Structure
| Property | Value |
|---|---|
| Full name | Thymosin Alpha-1 (Tα1) |
| Alternate names | TA-1; Zadaxin (pharmaceutical brand); thymalin (distinct extract formulation) |
| Sequence (single-letter) | SDAAVDTSSEITTKDLKEKKEVVEEAEN |
| Sequence (full names) | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| Peptide length | 28 amino acids |
| Molecular weight | ~3,108 Da |
| Molecular formula | C₁₂₉H₂₁₅N₃₃O₅₅ |
| N-terminal modification | N-terminal acetylation (Ac-Ser1) |
| Net charge (pH 7.4) | Approximately −3 (4 Lys basic; 3 Asp + 6 Glu acidic; predominately anionic) |
| Precursor protein | Prothymosin alpha (PTMA gene); TA-1 = residues 1–28 of the N-terminal domain |
| Proposed primary targets | TLR2; TLR9; dendritic cell maturation pathway; NK cell activation; T-cell differentiation (Th1 polarization) |
| CAS number | 62304-98-7 |
| Origin | Thymic tissue (bovine; isolation); research compound produced by solid-phase peptide synthesis |
3. Proposed Mechanisms of Action
4. Key Research Findings
4.1 Preclinical Innate Immune Studies
Cell culture and animal studies have documented TA-1’s capacity to stimulate dendritic cell maturation, enhance NK cell cytotoxicity, and induce Th1 cytokine profiles including IFN-γ, IL-12, and IL-2 across multiple experimental systems. A pivotal mechanistic study by Romani and colleagues demonstrated that TA-1 functions as a TLR2/TLR9 agonist in murine and human DC preparations, identifying a specific molecular basis for its innate immune activity and establishing its potential as a vaccine adjuvant [2]. Preclinical studies in immunocompromised and thymic-deficient animal models documented immune reconstitution effects, providing the rationale for early clinical development.
4.2 Hepatitis B Trials
Chronic hepatitis B (CHB) was the primary indication for which TA-1 entered controlled clinical trials. A placebo-controlled pilot trial by Mutchnick and colleagues reported that TA-1 monotherapy produced HBeAg seroconversion in a subset of CHB patients over 6 months of treatment, with a statistically significant difference versus placebo [3]. Subsequent randomized studies conducted primarily in Asian CHB populations, where hepatitis B prevalence is highest, evaluated TA-1 as monotherapy and in combination with interferon-alpha. Results across these trials were variable: some demonstrated improved HBeAg seroconversion and HBV DNA suppression, while others showed modest or no significant differences. The combination of TA-1 with interferon-alpha was generally better tolerated than interferon monotherapy, with TA-1 proposed to potentiate interferon’s antiviral signaling through upstream innate immune priming.
4.3 Hepatitis C Studies
TA-1 was also evaluated in chronic hepatitis C (CHC), where its proposed Th1-polarizing and IFN-α-potentiating properties were hypothesized to augment the interferon plus ribavirin standard of care. A randomized trial by Andreone and colleagues in patients with hepatitis C-associated liver cirrhosis reported outcomes with TA-1 and interferon combination versus interferon alone [4]. Across hepatitis C trials, results were mixed; the hepatitis C genotype landscape and the eventual development of direct-acting antiviral (DAA) drugs rendered the TA-1 + interferon combination clinically obsolete for most patients. Published HCV data represent an earlier era of interferon-based treatment paradigms and are difficult to translate to contemporary hepatitis C management.
4.4 Sepsis: The ETASS Trial
The most rigorous controlled trial of TA-1 published to date is the ETASS (Efficacy of Thymosin Alpha 1 for Severe Sepsis) trial by Wu and colleagues, a multicenter, single-blind, randomized controlled trial enrolling 361 patients with severe sepsis across multiple Chinese ICUs [5]. Patients received standard care plus either TA-1 (1.6 mg subcutaneous twice daily for 7 days) or standard care alone. The primary outcome was 28-day all-cause mortality. The TA-1 group showed a statistically significant reduction in 28-day mortality compared to standard care. Subgroup analysis suggested the mortality benefit was most pronounced in patients with lower initial immune activation (as measured by HLA-DR expression on monocytes), consistent with TA-1’s proposed immunoactivating role in immune-suppressed sepsis states. The ETASS findings are notable as one of the few positive large randomized trials of an immunomodulatory agent in severe sepsis.
Schematic representation of evidence depth at each research stage. Bar lengths are qualitative. TA-1 is distinguished from most compounds in this catalog by the existence of published randomized controlled trial data in human subjects.
4.5 COVID-19 and Emerging Applications
During the COVID-19 pandemic, TA-1 received renewed research attention based on its proposed capacity to restore immune function in states of immune exhaustion or immune paralysis — a pattern observed in severe SARS-CoV-2 infection characterized by lymphopenia, monocyte HLA-DR downregulation, and elevated anti-inflammatory cytokine levels. Multiple observational studies from Chinese and Italian centers reported that TA-1 administration in severe COVID-19 patients was associated with improved lymphocyte counts, reduced inflammatory markers, and, in some analyses, improved survival in critically ill patients. These observational data require cautious interpretation: they are not substitutes for placebo-controlled trial evidence, and confounding factors including concurrent treatments, disease severity distribution, and center-specific care protocols limit causal inference.
5. Evidence Status
| Proposed Effect | Current Status | Evidence Level |
|---|---|---|
| TLR2/TLR9 agonism and innate immune activation | Demonstrated in DC and macrophage cell systems; mechanism study published | Moderate |
| Dendritic cell maturation and Th1 polarization | Reported across multiple in vitro and animal systems; consistent data | Moderate |
| NK cell activation | Reported in cell culture; consistent with downstream cytokine milieu | Limited |
| Antiviral activity (hepatitis B) | Controlled trials with positive seroconversion outcomes; inconsistent across all studies | Moderate |
| Antiviral activity (hepatitis C) | Trials completed; results mixed; DAA drugs have superseded this use clinically | Limited |
| Mortality reduction in severe sepsis | Positive multicenter RCT (ETASS, 361 patients); single trial, Chinese ICU population | Moderate |
| COVID-19 outcomes | Observational studies only; no large placebo-controlled RCT published | Limited |
| Human pharmacokinetics after subcutaneous dosing | Half-life ~2 h after SC administration; PK data available from Phase I studies | Moderate |
6. Limitations of Current Research
References
- Low TL, Goldstein AL. “The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha 1 and polypeptide beta 1.” Journal of Biological Chemistry. 1979;254(3):987–995.
- Romani L, Fallarino F, De Luca A, et al. “Thymosin α1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance.” Journal of Clinical Investigation. 2012;122(3):1020–1031. doi:10.1172/JCI45694
- Mutchnick MG, Appelman HD, Chung HT, et al. “Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial.” Hepatology. 1991;14(3):409–415. doi:10.1002/hep.1840140312
- Andreone P, Cursaro C, Gramenzi A, et al. “A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis C virus cirrhosis.” Hepatology. 1996;24(4):774–777. doi:10.1002/hep.510240406
- Wu J, Zhou L, Liu J, et al. “The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.” Critical Care. 2013;17(1):R8. doi:10.1186/cc11932
- Garaci E. “Thymosin alpha1: a historical overview.” Annals of the New York Academy of Sciences. 2007;1112:14–20. doi:10.1196/annals.1415.039